SEPN Stock Analysis: Buy, Sell, or Hold?
SEPN - Septerna, Inc. Common Stock
$23.71
-0.58 (-2.39%)
▼
5d:
-8.31%
30d:
+1.76%
90d:
+0.21%
HOLD
LOW Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 21, 2026
21d
Get Alerted When SEPN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SEPN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SEPN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SEPN is currently trading at $23.71, which is considered slightly low relative to its 30-day fair value range of $23.70 to $25.54.
Technical Outlook: Technically, SEPN is in a downtrend. The price is currently testing key support at $23.31. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $44.43 (+82.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SEPN is in a downtrend. The price is currently testing key support at $23.31. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $44.43 (+82.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$23.70 -
$25.54
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 82.9% below Wall St target ($44.43)
- CAUTION: Recommendation downgraded due to -8.3% 5-day decline
Trading Range Analysis
30-Day Trading Range
$23.70 -
$25.54
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$23.31
Resistance Level
$27.30
Current Trend
Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.49
Wall Street Target
$44.43
(+82.9%)
Revenue Growth (YoY)
11276.4%
Profit Margin
-106.4%
Share & Embed Analysis
Last updated: April 29, 2026 11:51 AM ET
Data refreshes hourly during market hours. Next update: 12:51 PM
Data refreshes hourly during market hours. Next update: 12:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SEPN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Elizabeth Bhatt
SELL
4000 shares
2026-04-15
Samira Shaikhly
SELL
70453 shares
2026-03-02
Elizabeth Bhatt
SELL
4000 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 60 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 57 HOLD |
